Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Recent clinical trials have shown that immune-checkpoint blockade yields a clinical response in a subset of individuals with advanced nonsmall-cell lung cancer (NSCLC). We examined whether the expression of programmed death-ligand 1 (PD-L1) is related to clinicopathologic or prognostic factors in patients with surgically resected NSCLC.The expression of PD-L1 was evaluated by immunohistochemical analysis in 164 specimens of surgically resected...